https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50124 Wed 28 Feb 2024 16:17:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49984 Wed 28 Feb 2024 15:55:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50571 Wed 28 Feb 2024 15:53:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53799 Wed 28 Feb 2024 15:24:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47711 Wed 25 Jan 2023 10:55:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32651 30 kg/m²). Exacerbations requiring medical intervention were recorded prospectively. Asthma control, medication use, and fractional exhaled nitric oxide were assessed monthly; additional visits occurred during exacerbations. Peripheral blood was collected at baseline for the measurement of eosinophils, soluble CD-163, C-reactive protein, and IL-6. Results: Exacerbations occurred in a higher proportion of overweight (51.1%) and obese (48.4%) women compared with healthy weight women (25%; P =.026). Excess weight gain during pregnancy was not associated with exacerbation risk. Macrophage activation (elevated serum soluble CD-163) was associated with exacerbations requiring oral corticosteroids (P =.043), whereas high peripheral blood eosinophils or fractional exhaled nitric oxide were not associated with exacerbation or oral corticosteroid use. Conclusions: Being overweight or obese confers a greater risk of asthma exacerbation during pregnancy, and may be due to systemic macrophage activation.]]> Wed 19 Jan 2022 15:19:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50855 Wed 09 Aug 2023 09:52:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49079 Wed 03 May 2023 16:14:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41826 Tue 28 Mar 2023 11:27:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48581 Tue 21 Mar 2023 17:51:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48561 Tue 21 Mar 2023 15:45:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55707 Tue 18 Jun 2024 12:47:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55702 Tue 18 Jun 2024 12:40:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46337 P = .01), emergency visit (RR = 8.61, P = .03), and hospitalization (RR = 12.94, P < .01). Results of the cluster analysis were successfully validated in an independent PGA population classified using decision tree analysis. Although PGA can transform into or develop from other phenotypes, 70% were stable over time. Conclusions: Among 3 identified PGA clusters, cluster 3 had a higher risk of severe exacerbation. PGA heterogeneity indicates the requirement of novel targeted interventions.]]> Tue 15 Nov 2022 15:03:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47085 Tue 13 Dec 2022 16:35:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35593 Thu 28 Oct 2021 13:03:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54912 Thu 21 Mar 2024 12:03:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44713 Thu 20 Oct 2022 15:56:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33710 Thu 17 Feb 2022 09:25:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48386 2-agonist add-ons (54.1 vs 39.8%), and experienced significantly (P < .001) more exacerbations per year (median, 3 vs 2/y), worse asthma control, and worse lung function (% predicted postbronchodilator FEV1/forced vital capacity, 0.69 vs 0.72) versus nonreferred patients. Confirmed patients with severe asthma (ie, UK patients in the International Severe Asthma Registry) were younger (51 vs 65 years; P < .001), and significantly (P < .001) more likely to have uncontrolled asthma (91.4% vs 62.5%), a higher exacerbation rate (4/y [initial assessment] vs 3/y), use inhaled corticosteroid/long-acting β₂-agonist add-ons (67.7% vs 54.1%), and have nasal polyposis (24.2% vs 6.8) than referred patients with PSA. Conclusions: Large numbers of patients with PSA in the United Kingdom are underrecognized in primary care. These patients would benefit from a more systematic assessment in primary care and possible specialist referral.]]> Thu 16 Mar 2023 08:32:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49346 Thu 11 May 2023 16:31:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49876 3 mg/L), and depression. In both trials, TT treatment led to a large, significant improvement in HRQOL compared with usual care (Cohen's d = 1.19; P < .001). Receiving a statin for systemic inflammation and oral corticosteroid for eosinophilic airway inflammation was associated with the largest HRQOL improvements. Treatments for exercise intolerance, anxiety, and obesity were associated with smaller improvements in HRQOL. Conclusions: This study contributes to identifying clinically impactful TTs by showing that TTs across pulmonary, extrapulmonary, and behavioral domains were associated with HRQOL impairment and treatment response.]]> Thu 08 Jun 2023 15:21:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52233 Thu 05 Oct 2023 11:40:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50719 Thu 03 Aug 2023 09:12:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46835 Thu 01 Dec 2022 14:54:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38401 Mon 29 Jan 2024 17:48:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53947 Mon 24 Jun 2024 15:59:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49544 Mon 22 May 2023 08:45:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37007 ENO and symptoms (F_ENO group). Exacerbations were recorded prospectively. Height and weight were measured at baseline, and in late pregnancy. GWG was categorized according to Institute of Medicine guidelines. A validated parent-completed questionnaire assessed infant wheeze-related outcomes. Results: F_ENO-based management was associated with a significantly lower incidence rate ratio for maternal exacerbations in nonobese mothers (0.52, 95% confidence interval [CI], 0.31-0.88, P = .015, n = 129), and women with GWG within recommendations (0.35, 95% CI, 0.12-0.96, P = .042, n = 43), but not for obese mothers (0.59, 95% CI, 0.32-1.08, P = .089, n = 88), or women with excess GWG (0.58, 95% CI, 0.32-1.04, P = .07, n = 104). Recurrent bronchiolitis occurred in 5.3% (n = 1) of infants born to non-overweight mothers, 16.7% (n = 3) of infants of overweight mothers, and 21.7% (n = 5) of infants of obese mothers in the control group. In the F_ENO group, 2 infants of obese mothers had recurrent bronchiolitis (7.1%, P = .031). Conclusions: The benefits of F_ENO-based management are attenuated among obese mothers and those with excess GWG, indicating the importance of weight management in contributing to improved asthma management in pregnancy.]]> Mon 14 Nov 2022 20:28:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46219 Mon 14 Nov 2022 12:04:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46221 Mon 14 Nov 2022 12:04:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55058 Mon 08 Apr 2024 09:43:57 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55351 r > –0.19; P ≤ .03). Conclusions: Adults with severe asthma have worse core function than their control counterparts, independent of sex. Furthermore, as core function decreases, breathing symptoms increase.]]> Fri 17 May 2024 15:58:53 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55350 Fri 17 May 2024 15:57:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39682 Fri 17 Jun 2022 15:46:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46081 adj], 18.10 and 19.17, respectively) and mechanical ventilation (RR_adj , 2.56 and 5.71, respectively) than did cluster 1. Individuals in cluster 3 had an extended length of hospital stay (11 days), increased hospitalization direct costs (13,481.57 Chinese Yuan), and a higher risk of ICU admission (RR_adj , 2.14) than individuals in clusters 1 and 2. The decision tree assigned 90.8% of the participants correctly. Conclusions: We identified 3 phenotypes with differential clinical and inflammatory characteristics associated with in-hospital adverse outcomes. These new phenotypes might have important and clinically relevant implications for the management of patients hospitalized for AEs.]]> Fri 11 Nov 2022 15:15:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46047 Fri 11 Nov 2022 14:11:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46108 Fri 11 Nov 2022 13:50:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48167 Fri 10 Mar 2023 18:24:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37032 Fri 07 Aug 2020 09:12:14 AEST ]]>